Saturday 17 October 2026
Export OSTX’s income statement to Excel — free account
OS Therapies Incorporated
OSTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 5.26% and free cash flow fell 134.4%, each against the same quarter a year earlier.
1.32
0.09
−6.38%
Follow OSTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
0.56 | 0.03 | 0.05 | 0.18 |
Net Debt/EBITDA |
0.28 | 0.02 | 0.09 | 0.02 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.68 | 0.28 | 0.44 | 0.64 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
— | — | (135.03) | (1,531.36) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.74 | 0.95 | 0.87 | 0.63 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.15) | (0.13) | (0.12) | (0.13) | |
Cash per Share |
0.06 | 0.01 | 0.02 | 0.00 | |
Shareholders Equity per Share |
0.15 | (0.17) | (0.25) | (0.25) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.15 | (0.17) | (0.25) | (0.25) | |
Free Cash Flow |
(4.71) | (3.73) | (4.56) | (5.53) | |
Working Capital |
(1.82) | (11.43) | (16.04) | (17.00) | |
Net Current Asset Value |
(1.92) | (11.53) | (16.14) | (17.10) | |
| Other line items | |||||
Quick Ratio |
0.45 | 0.02 | 0.05 | 0.16 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.15) | (0.13) | (0.12) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
2.57 | 6.51 | 8.43 | 11.48 | |
Average Assets |
5.47 | 6.19 | 5.77 | 10.10 | |
Average Common Equity |
1.47 | (4.68) | (7.51) | (3.49) |
Columns are period end dates